Trending News

Breast cancer treatment
#Antibody drug conjugate (ADC) #Breast cancer #Cancer research #FDA #Gilead Sciences #GlobalData #Oncology

ADC potential “standard of care” for some breast cancer patients

The FDA has granted expanded approval for Gilead Sciences’ Trodelvy (sacituzumab govitecan-hziy) for patients with HR-positive/HER2-negative metastatic breast cancer who have received hormonal therapy and at least two additional therapies in the metastatic setting.  The drug is expected to become a standard of care for these patients,… Read More

#News #Trending News

MRI of the brain
#Clinical trial #Minoryx Therapeutics #Neurodegenerative disorders #Phase II trial

New treatment slows progression of neurodegenerative disease

Minoryx Therapeutics has revealed the findings from the first and largest international study to enroll adult male X-linked adrenoleukodystrophy patients.  The Phase II/III ADVANCE clinical trial of lead candidate, leriglitazone, published in The Lancet Neurology, did not meet the primary outcome… Read More

#News #Trending News

Hepatitis B
#hepatitis #Immunology / Virology & Vaccines #Immunotherapy #Phase II trial #siRNA #VBI Vaccines

Hepatitis B combination restores antibody and T cell responses

Biopharmaceutical company VBI Vaccines has revealed interim data from its Phase II study evaluating the combination of VBI-2601, VBI’s HBV immunotherapeutic candidate, and BRII-835, an HBV-targeting siRNA candidate, in chronically infected hepatitis B (HBV) patients.   The data demonstrate that the combination therapy was generally well-tolerated, restored strong… Read More

#News #Trending News

Blocked artery
#Aptamers #Basking Biosciences #ischaemic stroke #Phase I trial #RNA

RNA aptamer reopens blocked arteries

Biopharmaceutical company Basking Biosciences has revealed positive Phase I study results for its reversible thrombolytic therapeutic for ischaemic stroke.  The company’s novel von Willebrand Factor (vWF)-targeting thrombolytic agent, BB-031 demonstrated safety and tolerability following a single intravenous dose.   The study results were presented at the… Read More

#News #Trending News

Growing bacteria to create CAR therapy
#Cancer research #CAR-T #Immuno-oncology #Immunotherapy #Kite Pharma #National Institute for Health and Care Excellence (NICE) #NHS England #Oncology #UK

Ground-breaking CAR-T therapy approved in UK

Hundreds of people with an aggressive form of lymphoma are set to benefit from the first personalised immunotherapy treatment to be recommended for routine use in the NHS.  Axicabtagene ciloleucel (Yescarta, Kite) is a CAR-T therapy for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal… Read More

#News #Regulatory #Trending News

Multiple myeloma
#Cancer research #Myeloma #National Institute for Health and Care Excellence (NICE) #UK

NICE recommends triplet regimen for relapsed multiple myeloma

NICE has recommended Ninlaro (ixazomib) with lenalidomide and dexamethasone as an option relapsed or refractory multiple myeloma (RRMM) in adults who have received two or three lines of therapy.  Since its launch in December 2017, ixazomib has been funded through the Cancer Drugs Fund and has been used to treat… Read More

#Cancer Research #News #Regulatory #Trending News

#AAV #Cell and gene therapy #Drug delivery #Gene delivery #Gene therapy #mRNA #Nanomedicine / nanotechnology #Ophthalmology

Lipid nanoparticles and mRNA used to treat hereditary blindness

Oregon State University College of Pharmacy scientists have shown that lipid nanoparticles and messenger RNA could treat blindness associated with a rare genetic condition.  Researchers developed nanoparticles able to penetrate the neural retina and deliver mRNA to the photoreceptor cells whose proper function makes vision possible. … Read More

#News #Trending News

#AbbVie #ABPI #Clinical trials #Eli Lilly #Life sciences #Pharmaceutical industry #Pharmaceuticals #UK #UK government

Pharma firms pull out of UK drug pricing agreement

AbbVie and Eli Lilly have left the voluntary medicines pricing agreement in protest over what they describe as “increasingly punitive revenue clawbacks”.  The companies have left the UK’s Voluntary Scheme for Branded Medicines Pricing and Access (VPAS), a long-standing agreement between government and industry with roots going back to the… Read More

#Business & Investment #News #Trending News

Blood in a Petri dish
#BioMarin Pharmaceuticals #Cell and gene therapy #Gene therapy #Haemophilia #Orphan drugs #Phase III trial

Haemophilia one-time gene therapy effective for three years

An investigational one-time gene therapy for the treatment of adults with severe haemophilia A has been proven to be effective for more than three years from treatment.  BioMarin Pharmaceutical revealed the positive results from its ongoing global Phase III GENEr8-1 study of Roctavian (valoctocogene roxaparvovec).  … Read More

#News #Trending News

Vaccine production
#BioNTech #Cancer immunotherapy #Cancer research #Clinical trials #Immunotherapy #Moderna #mRNA #mRNA-based vaccines #Personalised medicine #UK government

New UK partnership to accelerate mRNA research

It is hoped that a new partnership between the UK government and BioNTech will help accelerate clinical trials of personalised immunotherapies for cancer and infectious disease vaccines.  The agreement means cancer patients will get early access to trials exploring personalised mRNA therapies, like cancer vaccines.  Professor Uğur Şahin, Chief Executive… Read More

#Business & Investment #Cancer Research #News #Trending News

Cancer cells
#Brain disease #Cancer research #Cell and gene therapy #CRISPR #CRISPR-Cas9 #Gene editing #Mouse models #Neuroscience #Oncology

Scientists turn cancer cells into anticancer agents

Harvard investigators have developed a new cell therapy approach to eliminate established tumours and induce long-term immunity.   In this early research, Khalid Shah, Professor of Neurosurgery at Harvard Medical School and Brigham and Women’s Hospital, and colleagues tested the vaccine in an advanced mouse model of brain… Read More

#Cancer Research #News #Trending News

Urinary system
#Bicycle Therapeutics #Cancer research #FDA #Oncology #United States

FDA fast-tracks metastatic urothelial cancer treatment

The United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to Bicycle Therapeutics’ BT8009 monotherapy for the treatment of adult patients with previously treated locally advanced or metastatic urothelial cancer.   BT8009 is a potential first in class Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a protein that… Read More

#Cancer Research #News #Regulatory #Trending News

Antibodies attack Covid-19
#AstraZeneca #Covid-19 #Covid-19 treatment #Immunity #Monoclonal antibodies

Accelerated development for Covid-19 monoclonal antibody

A monoclonal antibody to prevent Covid-19 in vulnerable patients, AZD3152, has entered clinical trials less than 12 months after discovery.  AstraZeneca has initiated the SUPERNOVA Phase I/III trial of AZD5156 (a combination of AZD3152 and cilgavimab) in pre-exposure prophylaxis of Covid-19, following the company licensing AZD3152 from… Read More

#Covid-19 #News #Trending News

Prostate-specific membrane antigen
#Cancer research #Europe #Novartis #Oncology #Prostate cancer

New prostate cancer drug approved in Europe

A new drug based on the active ingredient Lutetium-177 PSMA-617 has been approved by the European Commission for the treatment of metastatic prostate cancer carrying the surface molecule PSMA (prostate specific membrane antigen).   The drug was developed under the leadership of the German Cancer Research Center (DKFZ)… Read More

#Cancer Research #News #Trending News

Gene therapy for haemophilia
#Cell and gene therapy #CHMP #CSL #Europe #Gene therapy #Haemophilia

First gene therapy for haemophilia B gets go ahead in Europe

The first gene therapy for haemophilia B could soon be available to patients in Europe following a positive opinion from the Committee for Medicinal Products for Human Use (CHMP).  The CHMP has recommended conditional marketing authorisation of CSL’s etranacogene dezaparvovec, a one-time gene therapy for the treatment of appropriate adults… Read More

#News #Regulatory #Trending News

Epidermolysis bullosa patient has foot bandaged
#Clinical trial #Dermatology #Epidermolysis bullosa #Gene delivery #Gene therapy

‘Life-changing’ topical gene therapy gel heals EB wounds

Researchers have found that a topical gene therapy gel helps heal wounds in patients with life-threatening blistering skin disease epidermolysis bullosa (EB).  People with dystrophic epidermolysis bullosa often suffer from large open wounds that last for years or decades. It’s an intensely painful condition, and medical treatment… Read More

#News #Trending News